Lynozyfic could have an edge over rival BCMA-targeting bispecifics.

Some big deals in the second quarter have raised hopes that takeouts are back.

Zegfrovy is approved in a best-case setting, but Dizal has no US presence.

Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.

The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.

Regeneron is facing two FDA decisions for its T-cell engagers.